{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":634,"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system","id":"EG000","otherNumAffected":0,"otherNumAtRisk":634,"seriousNumAffected":0,"seriousNumAtRisk":634,"title":"Primary Hyperparathyroidism - Incomplete Data"},{"deathsNumAffected":0,"deathsNumAtRisk":900,"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications","id":"EG001","otherNumAffected":0,"otherNumAtRisk":900,"seriousNumAffected":0,"seriousNumAtRisk":900,"title":"Primary Hyperparathyroidism"},{"deathsNumAffected":0,"deathsNumAtRisk":19,"description":"Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA\n\n68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.\n\n18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.","id":"EG002","otherNumAffected":1,"otherNumAtRisk":19,"seriousNumAffected":0,"seriousNumAtRisk":19,"title":"DOTATATE and F-DOPA"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAtRisk":634},{"groupId":"EG001","numAffected":0,"numAtRisk":900},{"groupId":"EG002","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Abdominal pain"}],"timeFrame":"3 months"}